CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (800) 466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-10-25 | Nuechterlein Carole Director | Purchase | +7,933,601 | $0.76 | $6.0M | 11,025,941 |
| 2020-10-20 | Novo Holdings A/S 10% owner | Purchase | +200,000 | $15.00 | $3.0M | 2,614,563 |
| 2020-10-20 | Woiwode Thomas Director | Purchase | +200,000 | $15.00 | $3.0M | 862,444 |
| 2020-10-20 | Vivo Capital VIII, LLC 10% owner | Purchase | +483,267 | $15.00 | $7.2M | 3,116,658 |
| 2020-10-20 | Vivo Capital VIII, LLC 10% owner | Purchase | +66,733 | $15.00 | $1.0M | 430,372 |
| 2020-10-20 | Versant Venture Capital VI, L.P. 10% owner | Purchase | +200,000 | $15.00 | $3.0M | 862,444 |
Page 1 of 1 · 6 trades